CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.

Wall Street analysts forecast CTMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTMX is 6.50 USD with a low forecast of 3.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CytomX Therapeutics Inc revenue for the last quarter amounts to 5.96M USD, decreased -82.16 % YoY.

CytomX Therapeutics Inc. EPS for the last quarter amounts to -0.09 USD, decreased -228.57 % YoY.

CytomX Therapeutics Inc (CTMX) has 119 emplpoyees as of December 15 2025.

Today CTMX has the market capitalization of 709.93M USD.